Publikationen, an denen er mitarbeitet Borja Guerra Hernández (9)

2022

  1. Design, Semisynthesis, and Estrogenic Activity of Lignan Derivatives from Natural Dibenzylbutyrolactones

    Pharmaceuticals, Vol. 15, Núm. 5, pp. 585

  2. Discovery of Highly Functionalized 5-hydroxy-2H-pyrrol-2-ones That Exhibit Antiestrogenic Effects in Breast and Endometrial Cancer Cells and Potentiate the Antitumoral Effect of Tamoxifen

    Cancers, Vol. 14, Núm. 21

2021

  1. JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia

    Biomedicine and Pharmacotherapy, Vol. 144

  2. Modular synthesis and antiproliferative activity of new dihydro-1H-pyrazolo[1,3-b]pyridine embelin derivatives

    Pharmaceuticals, Vol. 14, Núm. 10

2019

  1. A novel naphthoquinone-coumarin hybrid that inhibits BCR-ABL1-STAT5 oncogenic pathway and reduces survival in imatinib-resistant chronic myelogenous leukemia cells

    Frontiers in Pharmacology, Vol. 9, Núm. JAN

  2. Signal transducer and activator of transcription (STAT)-5: an opportunity for drug development in oncohematology

    Oncogene, Vol. 38, Núm. 24, pp. 4657-4668

  3. Synthesis, characterization and antiproliferative activity of mixed ligand complexes of Cu2+ and Co2+ with lapachol

    Polyhedron, Vol. 165, pp. 73-78

2018

  1. Correction: CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia [Oncotarget, 8 (2017) (29679-29698)] Doi: 10.18632/oncotarget.11425

    Oncotarget

2017

  1. CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia

    Oncotarget, Vol. 8, Núm. 18, pp. 29679-29698